Arvinas, Inc. (ARVN) Stock Price & Analysis
Arvinas, Inc. (ARVN) rose 0.86% to USD 9.39 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
ARVN last closed at USD 9.31; the session ranged USD 9.22–9.46 on volume of 449,298 shares. Market capitalization is $605.85M, with a 52-week range of USD 6.97–14.51 (NMS). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 9.39 |
|---|---|
| Change | ▲ 0.86% (up) |
| Previous Close | USD 9.31 |
| Open | USD 9.31 |
| Day Range | USD 9.22 – 9.46 |
| 52-Week Range | USD 6.97 – 14.51 |
| Volume | 449,298 shares |
| Market Cap | $605.85M |
| Exchange | NMS |
Technical Analysis (ARVN)
Nexqual's technical model rates ARVN "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.81 (neutral) |
| vs SMA50 | Above (USD 8.67) |
| MACD | 0.21 (positive) |
Analyst Ratings (ARVN)
Wall Street analysts rate ARVN "Buy" based on 14 analysts, with a mean price target of USD 13.93 (range USD 6–21), per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 13.93 |
| High Target | USD 21 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 7 / 8 / 1 |
Earnings (ARVN)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.94 |
| Revenue Estimate | $16.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.58 vs est -0.28 ▲ beat |
| 2026-03-31 | USD -0.9 vs est -0.96 ▲ beat |
| 2025-12-31 | USD -1.1 vs est -0.57 ▼ miss |
| 2025-09-30 | USD -0.48 vs est -0.74 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (ARVN)
| Total Revenue | $316.70M |
|---|---|
| Revenue Growth (YoY) | +1014.70% |
| Gross Margin | +97.16% |
| Operating Margin | +66.36% |
| Profit Margin | +2.94% |
| ROE | +1.59% |
| Debt / Equity | 1.42 |
| Current Ratio | 7.91 |
| Total Cash | $567.90M |
| Total Debt | $8.00M |
| Free Cash Flow | $-94.50M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (ARVN)
Nexqual rates Arvinas, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Strong — Operating margin 66% |
| Balance Sheet | Strong — $568M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$95M, burning cash |
| Efficiency | Weak — ROE 2%, ROA -1.0% |
Ownership (ARVN)
| Insider Ownership | +7.80% |
|---|---|
| Institutional Ownership | +84.20% |
| Shares Outstanding | 64.52M |
| Float | 56.81M |
| Short % of Float | +7.22% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (ARVN)
Arvinas, Inc. is led by Randy Teel (age 45), CEO, President & Director, per Nexqual as of September 8, 2026 at 05:44 UTC.
| CEO, President & Director | Randy Teel (age 45) |
|---|---|
| CFO & Treasurer | Andrew R. Saik (age 56) |
| Chief Scientific Officer | Angela M. Cacace (age 57) |
| Vice President of Investor Relations | Jeff Boyle |
| Senior Vice President of Regulatory Affairs | Paul McInulty |
Major Backers & Investors (ARVN)
Notable institutional backers of Arvinas, Inc. include Shaw D.E. & Co., Inc., Pfizer Inc, Armistice Capital, LLC, according to Nexqual as of September 8, 2026 at 05:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shaw D.E. & Co., Inc. | 5.42% |
| Pfizer Inc | 5.36% |
| Armistice Capital, LLC | 4.33% |
| Two Sigma Investments, LP | 3.99% |
| Qube Research & Technologies Ltd | 2.47% |
| Fidelity | 1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.51% |
| BlackRock | 15.8% |
| State Street | 4.53% |
| Geode Capital | 2.58% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
From Arvinas, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression.
- We have also created a proprietary software tool to accelerate LEAP library design. • PROTACify : We have built PROTACify, a proprietary computational, machine-learning, or ML, solution for modeling PROTAC ternary complexes to enable selection of the best PROTAC designs for synthesis.
- We believe favorable clinical trial results in our ongoing oncology and neurology programs would further validate our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins.
- With our integrated capabilities we aim to accelerate discovery of TPD therapeutics, translating biological insight into efficient drug design.
Partnerships
- In July 2021, we announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 117.39 | ▼ 1.05% |
| DNLI | Denali Therapeutics Inc. | USD 22.28 | ▼ 2.49% |
| RCKT | Rocket Pharmaceuticals, Inc. | USD 3.86 | ▲ 0% |
| RCUS | Arcus Biosciences, Inc. | USD 29.66 | ▼ 0.64% |
| ALEC | Alector, Inc. | USD 2.46 | ▼ 9.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.